Kura Oncology, Inc. (NASDAQ:KURA) Investor Notice: Investigation Over Potential Wrongdoing

An investigation on behalf of investors in Kura Oncology, Inc. (NASDAQ:KURA) shares over potential wrongdoing at Kura Oncology, Inc. was announced.

San Diego, CA — (SBWIRE) — 03/04/2022 — Certain directors of Kura Oncology, Inc are under investigation over potential breaches of fiduciary duties.

Investors who purchased shares of Kura Oncology, Inc. (NASDAQ: KURA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The investigation by a law firm concerns whether certain Kura Oncology, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

San Diego, CA based Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States.

On November 24, 2021, Kura Oncology, Inc. “announced that the U.S. Food and Drug Administration (FDA) has placed the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML) on a partial clinical hold.” Kura Oncology, Inc. advised that “[t]he partial clinical hold was initiated following the Company’s recent report to the FDA of a Grade 5 serious adverse event (patient death) potentially associated with differentiation syndrome, a known adverse event related to differentiating agents in the treatment of AML[,]” and that “[u]ntil the partial clinical hold is resolved, and the Company has more clarity regarding the impact on timing, Kura is suspending guidance on the completion of enrollment in the KOMET-001 Phase 1b study and determination of the recommended Phase 2 dose of KO-539.”

Those who purchased shares of Kura Oncology, Inc. (NASDAQ: KURA) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit: http://www.sbwire.com/press-releases/kura-oncology-inc-nasdaqkura-investor-notice-investigation-potential-1354203.htm

Media Relations Contact

Michael Daniels
Shareholders Foundation
Telephone: 1-858-779-1554
Email: Click to Email Michael Daniels
Web: https://www.shareholdersfoundation.com/